adjuvant technology News
-
Medigen and BlueWillow Biologics Partner to Develop Intranasal Vaccine for SARS-CoV-2
Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO), a biopharmaceutical company focusing on the development and production of vaccines and biologics, and BlueWillow Biologics, Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines through its patented NanoVax™ adjuvant, today announced a partnership to develop S-2P-NE-01, a nasal vaccine for ...
-
Dynavax Highlights 2022 Priorities and Announces Initiation of Phase 1 Clinical Trial for Its Shingles Vaccine Candidate
Dynavax expects year over year revenue growth for HEPLISAV-B and CpG 1018 adjuvant to drive continued profitability in 2022 Strong financial position supports investment in long-term growth drivers including pipeline expansion Initiation of Phase 1 clinical trial of shingles vaccine candidate, adjuvanted with CpG 1018, with data expected year end 2022 Dynavax Technologies Corporation ...
-
POP BIO awarded $599,981 Phase 1 SBIR Award to Develop Thermostable COVID-19 Vaccine
BUFFALO, N.Y. — POP Biotechnologies Inc. (POP BIO) received a $599,981, two-year Phase I Small Business Innovation Research (SBIR) under Award No. 1R43AI165089-01, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to pursue development of a potentially life-saving vaccine technology to address the ongoing ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you